1. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Issue 7 (1st March 2023) Authors: Francis, Prudence A.; Fleming, Gini F.; Láng, István; Ciruelos, Eva M.; Bonnefoi, Hervé R.; Bellet, Meritxell; Bernardo, Antonio; Climent, Miguel A.; Martino, Silvana; Bermejo, Begoña; Burstein, Harold J.; Davidson, Nancy E.; Geyer, Charles E.; Walley, Barbara A.; Ingle, James N.; Coleman, Robert... Journal: Journal of clinical oncology Issue: Volume 41:Issue 7(2023) Page Start: 1370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. Issue 7 (1st March 2023) Authors: Pagani, Olivia; Walley, Barbara A.; Fleming, Gini F.; Colleoni, Marco; Láng, István; Gomez, Henry L.; Tondini, Carlo; Burstein, Harold J.; Goetz, Matthew P.; Ciruelos, Eva M.; Stearns, Vered; Bonnefoi, Hervé R.; Martino, Silvana; Geyer, Charles E.; Chini, Claudio; Puglisi, Fabio; Spazzapan, Simon... Journal: Journal of clinical oncology Issue: Volume 41:Issue 7(2023) Page Start: 1376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. (June 2022) Authors: Martín, Miguel; Zielinski, Christoph; Ruiz-Borrego, Manuel; Carrasco, Eva; Ciruelos, Eva M.; Muñoz, Montserrat; Bermejo, Begoña; Margelí, Mireia; Csöszi, Tibor; Antón, Antonio; Turner, Nicholas; Casas, María I.; Morales, Serafín; Alba, Emilio; Calvo, Lourdes; de la Haba-Rodríguez, Juan; Ramos, Ma... Journal: European journal of cancer Issue: Volume 168(2022) Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07). (23rd June 2020) Authors: Ciruelos, Eva M.; Montaño, Alvaro; Rodríguez, César A.; González‐Flores, Encarnación; Lluch, Ana; Garrigós, Laia; Quiroga, Vanesa; Antón, Antonio; Malón, Diego; Chacón, Jose I.; Velasco, Montserrat; Gonzalez‐Cortijo, Lucía; Jolis, Laura; Echarri, María J.; Muñoz, Montse; Pascual, Tomás; Amigo, Yo... Journal: European journal of cancer care Issue: Volume 29:Number 4(2020) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC). (October 2021) Authors: Rugo, Hope S.; André, Fabrice; Park, Yeon Hee; Drullinsky, Pamela; Loibl, Sibylle; Cardoso, Fátima; Mason, Ginny; Aubel, Dawn; Lorenzo, Inés; Akdere, Murat; Ciruelos, Eva M. Journal: Breast Issue: Volume 59(2021)supplement 1 Page Start: S49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗